Sangamo BioSciences announces positive data for Vivo Protein platform Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach.
Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire.